Maxim Group analyst Jason McCarthy maintained a Hold rating on Bluebird Bio (NASDAQ: BLUE) today. The company’s shares opened today at $140.80, close to its 52-week low of $125.30.
McCarthy commented:
“bluebird announced that the EMA has accepted the company’s MAA submission LentiGlobin for the treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT) harboring non-β 0 /β 0 genotype. While the news was expected based on the clinical path forward in Europe and bluebird’s previously announced timelines, we view this as a significant positive for the company and the space as this is the first of BLUE’s likely multiple gene therapy and CAR-T filings over the next several years.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 19.6% and a 54.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $223.38.
See today’s analyst top recommended stocks >>
The company has a one-year high of $236.17 and a one-year low of $125.30. Currently, Bluebird Bio has an average volume of 647K.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLUE in relation to earlier this year. Most recently, in August 2018, Jason Cole, the CLO of BLUE bought 4,438 shares for a total of $99,988.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.
